Mesenchymal Stem Cells Express Serine Protease Inhibitor to Evade the Host Immune Response

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2010 Nov 16

PMID 21076046

Citations 22

Authors

Najib El Haddad

Dean Heathcote

Robert Moore

Sunmi Yang

Jamil Azzi

Bechara Mfarrej

Mark Atkinson

Mohamed H Sayegh

Jeng-Shin Lee

Philip G Ashton-Rickardt

Reza Abdi

Affiliations

Soon will be listed here.

Abstract

Clinical trials using mesenchymal stem cells (MSCs) have been initiated worldwide. An improved understanding of the mechanisms by which allogeneic MSCs evade host immune responses is paramount to regulating their survival after administration. This study has focused on the novel role of serine protease inhibitor (SPI) in the escape of MSCs from host immunosurveillance through the inhibition of granzyme B (GrB). Our data indicate bone marrow-derived murine MSCs express SPI6 constitutively. MSCs from mice deficient for SPI6 (SPI6(-/-)) exhibited a 4-fold higher death rate by primed allogeneic cytotoxic T cells than did wild-type MSCs. A GrB inhibitor rescued SPI6(-/-) MSCs from cytotoxic T-cell killing. Transduction of wild-type MSCs with MigR1-SPI6 also protected MSCs from cytotoxic T cell-mediated death in vitro. In addition, SPI6(-/-) MSCs displayed a shorter lifespan than wild-type MSCs when injected into an allogeneic host. We conclude that SPI6 protects MSCs from GrB-mediated killing and plays a pivotal role in their survival in vivo. Our data could serve as a basis for future SPI-based strategies to regulate the survival and function of MSCs after administration and to enhance the efficacy of MSC-based therapy for diseases.

Citing Articles

Non-small cell lung cancer cells and concomitant cancer therapy induce a resistance-promoting phenotype of tumor-associated mesenchymal stem cells.

Sentek H, Braun A, Budeus B, Klein D Front Oncol. 2024; 14:1406268.

PMID: 39011489 PMC: 11246879. DOI: 10.3389/fonc.2024.1406268.

The biological function of Serpinb9 and Serpinb9-based therapy.

Huang H, Mu Y, Li S Front Immunol. 2024; 15:1422113.

PMID: 38966643 PMC: 11222584. DOI: 10.3389/fimmu.2024.1422113.

Comparative computational analysis to distinguish mesenchymal stem cells from fibroblasts.

Budeus B, Unger K, Hess J, Sentek H, Klein D Front Immunol. 2023; 14:1270493.

PMID: 37822926 PMC: 10562561. DOI: 10.3389/fimmu.2023.1270493.

CXCR4 enhances the inhibitory effects of bone mesenchymal stem cells on lung cell apoptosis in a rat model of smoking-induced COPD.

Gao J, Liang Y, Chen J, Shen H, Liu H Apoptosis. 2023; 28(3-4):639-652.

PMID: 36719470 PMC: 9888343. DOI: 10.1007/s10495-022-01800-6.

Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy.

Jiang L, Wang Y, Zhao J, Uehara M, Hou Q, Kasinath V Cell. 2020; 183(5):1219-1233.e18.

PMID: 33242418 PMC: 7927154. DOI: 10.1016/j.cell.2020.10.045.

References

Sadan O, Melamed E, Offen D . Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. Expert Opin Biol Ther. 2009; 9(12):1487-97. DOI: 10.1517/14712590903321439. View

Sayegh M, Turka L . The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med. 1998; 338(25):1813-21. DOI: 10.1056/NEJM199806183382506. View

Wang X, Terasaki P, Rankin Jr G, Chia D, Zhong H, Hardy S . A new microcellular cytotoxicity test based on calcein AM release. Hum Immunol. 1993; 37(4):264-70. DOI: 10.1016/0198-8859(93)90510-8. View

Papadopoulos N, Dedoussis G, Spanakos G, Gritzapis A, Baxevanis C, Papamichail M . An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry. J Immunol Methods. 1994; 177(1-2):101-11. DOI: 10.1016/0022-1759(94)90147-3. View

Sun J, Bird C, SUTTON V, McDonald L, Coughlin P, de Jong T . A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem. 1996; 271(44):27802-9. DOI: 10.1074/jbc.271.44.27802. View

Medema J, de Jong J, Peltenburg L, Verdegaal E, Gorter A, Bres S . Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A. 2001; 98(20):11515-20. PMC: 58761. DOI: 10.1073/pnas.201398198. View

Shresta S, Heusel J, MacIvor D, Wesselschmidt R, Russell J, Ley T . Granzyme B plays a critical role in cytotoxic lymphocyte-induced apoptosis. Immunol Rev. 1995; 146:211-21. DOI: 10.1111/j.1600-065x.1995.tb00690.x. View

Rasmusson I . Immune modulation by mesenchymal stem cells. Exp Cell Res. 2006; 312(12):2169-79. DOI: 10.1016/j.yexcr.2006.03.019. View

Phillips T, Opferman J, Shah R, Liu N, Froelich C, Ashton-Rickardt P . A role for the granzyme B inhibitor serine protease inhibitor 6 in CD8+ memory cell homeostasis. J Immunol. 2004; 173(6):3801-9. DOI: 10.4049/jimmunol.173.6.3801. View

10.

Jones B, McTaggart S . Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol. 2008; 36(6):733-41. DOI: 10.1016/j.exphem.2008.03.006. View

11.

Uccelli A, Moretta L, Pistoia V . Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2009; 8(9):726-36. DOI: 10.1038/nri2395. View

12.

Cullen S, Martin S . Mechanisms of granule-dependent killing. Cell Death Differ. 2007; 15(2):251-62. DOI: 10.1038/sj.cdd.4402244. View

13.

Abdi R, Fiorina P, Adra C, Atkinson M, Sayegh M . Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes. 2008; 57(7):1759-67. PMC: 2453631. DOI: 10.2337/db08-0180. View

14.

Hirst C, Buzza M, Bird C, Warren H, Cameron P, Zhang M . The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. J Immunol. 2003; 170(2):805-15. DOI: 10.4049/jimmunol.170.2.805. View

15.

Greiner D, Hesselton R, Shultz L . SCID mouse models of human stem cell engraftment. Stem Cells. 1998; 16(3):166-77. DOI: 10.1002/stem.160166. View

16.

Pistoia V, Raffaghello L . Potential of mesenchymal stem cells for the therapy of autoimmune diseases. Expert Rev Clin Immunol. 2010; 6(2):211-8. DOI: 10.1586/eci.09.86. View

17.

Rasmusson I, Uhlin M, Le Blanc K, Levitsky V . Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol. 2007; 82(4):887-93. DOI: 10.1189/jlb.0307140. View

18.

Luo X, Budihardjo I, Zou H, Slaughter C, Wang X . Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998; 94(4):481-90. DOI: 10.1016/s0092-8674(00)81589-5. View

19.

De Bari C, DellAccio F . Mesenchymal stem cells in rheumatology: a regenerative approach to joint repair. Clin Sci (Lond). 2007; 113(8):339-48. DOI: 10.1042/CS20070126. View

20.

Nauta A, Westerhuis G, Kruisselbrink A, Lurvink E, Willemze R, Fibbe W . Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006; 108(6):2114-20. PMC: 1895546. DOI: 10.1182/blood-2005-11-011650. View